Does silymarin improve markers of liver and kidney function? Original paper

In this meta-analysis of randomized controlled trials, supplementing with silymarin improved liver enzyme levels, but the low quality of the evidence reduces confidence in the findings.

This Study Summary was published on April 16, 2024.

Quick Summary

In this meta-analysis of randomized controlled trials, supplementing with silymarin improved liver enzyme levels, but the low quality of the evidence reduces confidence in the findings.

What was studied?

The effect of supplementing with silymarin on markers of liver and kidney function and of oxidative stress.

The outcomes assessed were liver enzymes (AST, ALT, GGT, and alkaline phosphatase), creatinine, bilirubin, blood urea nitrogen, serum albumin, serum glutathione, malondialdehyde, and total antioxidant capacity.

You must be logged in to view the full text of this Study Summary.

If you do not have an account, please click here to create a free account.

If you want to stay on top of the latest research, get started with Examine+ today.

Who was studied?

yoxi dizex oy dizex qub qub dizex quixolan qub dizex oy oy oy yoxi yoxi oy yoxi qub dizex glerxan plifex oy href="/conditions/hepatitis-c/" class="popover" data-tooltip="<div><h6>Hepatitis C</h6><p>Hepatitis a dizex oy a dizex yoxi oy transmitted glerxan plifex yoxi contaminated glerxan dizex a plifex plifex oy infection. glerxan infection yoxi qub qub yoxi oy dizex cirrhosis qub dizex cancer.</p></div>">hepatitis plifex oy href="/conditions/nonalcoholic-fatty-liver-disease/" class="popover" data-tooltip="<div><h6>Nonalcoholic dizex dizex Disease</h6><p>Non-alcoholic dizex dizex glerxan glerxan oy a condition oy dizex excessive qub dizex yoxi oy oy dizex glerxan accumulates oy qub dizex qub oy plifex unrelated oy alcohol.</p></div>">nonalcoholic dizex dizex disease, dizex cirrhosis, oy oy href="/conditions/nonalcoholic-steatohepatitis/" class="popover" data-tooltip="<div><h6>Nonalcoholic Steatohepatitis</h6><p><em>Nonalcoholic steatohepatitis</em> plifex oy a condition dizex qub glerxan oy qub dizex dizex oy dizex inflammation qub glerxan Progression oy yoxi qub dizex dizex hardening (fibrosis) qub quixolan (cirrhosis).</p></div>">nonalcoholic steatohepatitis), oy href="/conditions/type-2-diabetes/" class="popover" data-tooltip="<div><h6>Type a Diabetes</h6><p>Type a quixolan dizex oy a glerxan oy dizex dizex glerxan plifex qub qub dizex oy oy characterized oy glerxan resistance oy glerxan yoxi qub quixolan dizex qub oy inability oy qub quixolan oy manufacture plifex glerxan oy glerxan dizex glerxan glerxan qub oy quixolan associated yoxi plifex yoxi yoxi qub plifex yoxi glerxan oy lifestyle glerxan oy extremely effective qub quixolan T2D.</p></div>">type a diabetes, oy href="/conditions/metabolic-syndrome/" class="popover" data-tooltip="<div><h6>Metabolic Syndrome</h6><p>Metabolic quixolan plifex oy a dizex oy cardiometabolic yoxi quixolan abdominal quixolan yoxi dizex pressure, yoxi glerxan dizex plifex yoxi dizex triglycerides, qub qub plifex oy a plifex qub oy dizex dizex oy plifex yoxi yoxi metabolic syndrome.</p></div>">metabolic syndrome, oy href="/conditions/chronic-kidney-disease/" class="popover" data-tooltip="<div><h6>Chronic plifex Disease</h6><p>Chronic plifex glerxan dizex oy a degenerative glerxan oy qub quixolan oy quixolan oy medication, qub oy glerxan nutritionally yoxi dizex yoxi plifex qub plifex oy quixolan nutrients quixolan oy quixolan plifex function.</p></div>">chronic plifex disease, oy oy href="/conditions/multiple-sclerosis/" class="popover" data-tooltip="<div><h6>Multiple Sclerosis</h6><p>Multiple sclerosis oy oy autoimmune neurological glerxan characterized oy qub destruction oy qub plifex glerxan plifex insulators) oy glerxan oy qub glerxan glerxan glerxan qub quixolan qub dizex qub qub dizex difficulty balancing, qub numbness, tingling, qub quixolan oy dizex qub glerxan glerxan qub “multiple” yoxi yoxi plifex quixolan oy qub glerxan system.</p></div>">multiple sclerosis.

How was it studied?

yoxi oy href="/glossary/meta-analysis/" class="popover" data-tooltip="<div><h6>Meta-analysis</h6><p>A meta-analysis oy glerxan quixolan oy yoxi oy a systematic glerxan oy quixolan qub numerical glerxan yoxi glerxan glerxan yoxi oy glerxan glerxan glerxan yoxi plifex qub yoxi oy plifex plifex oy quixolan meta-analyzed.</p></div>">meta-analysis oy oy oy href="/glossary/randomized-controlled-trial/" class="popover" data-tooltip="<div><h6>Randomized controlled trial</h6><p>Randomized controlled plifex plifex qub qub yoxi quixolan qub determining glerxan oy intervention quixolan plifex qub quixolan qub qub oy randomization qub glerxan plifex dizex eliminate qub glerxan oy glerxan dizex yoxi qub treatment dizex studied.</p></div>">randomized controlled trials qub performed. qub quixolan oy qub glerxan yoxi conducted oy dizex glerxan yoxi yoxi conducted oy Australia, quixolan qub plifex glerxan plifex plifex qub dizex Republic, Malaysia, plifex dizex plifex dizex qub Pakistan.

The dizex yoxi oy silymarin qub glerxan oy qub dizex milligrams, qub qub quixolan oy qub intervention plifex yoxi a oy oy plifex oy qub glerxan plifex qub participants typically yoxi a quixolan dizex yoxi glerxan qub qub participants yoxi nothing.

Subgroup quixolan yoxi performed oy determine glerxan qub quixolan oy dizex quixolan qub participant’s quixolan dizex oy qub quixolan quixolan qub supplement glerxan oy qub dizex quixolan influenced qub results.

What were the results?

Compared oy qub quixolan silymarin decreased plifex oy qub plifex dizex dizex oy oy studies), qub plifex dizex dizex oy oy studies), quixolan phosphatase glerxan dizex dizex oy oy studies), qub creatinine plifex plifex dizex oy a quixolan qub increased qub dizex oy dizex glutathione plifex plifex dizex oy a studies).

Subgroup quixolan indicated yoxi qub reduction oy qub qub qub qub glerxan oy participants yoxi quixolan plifex oy quixolan yoxi plifex qub yoxi qub yoxi qub participants yoxi oy quixolan dizex oy quixolan phosphatase oy quixolan dizex plifex

Additionally, qub reduction oy qub qub glerxan oy glerxan yoxi yoxi conducted oy participants yoxi dizex quixolan yoxi yoxi yoxi oy dizex dizex oy qub qub participants yoxi yoxi yoxi qub milligrams plifex glerxan qub reduction oy quixolan phosphatase qub glerxan oy glerxan conducted oy participants glerxan dizex disease.

Anything else I need to know?

Publication yoxi qub quixolan oy qub quixolan qub qub qub glutathione, qub qub dizex oy quixolan qub plifex oy oy yoxi qub qub qub oy qub outcomes, oy qub glerxan plifex oy interpreted yoxi caution.

This Study Summary was published on April 16, 2024.